Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
Κύριοι συγγραφείς: | Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ |
---|---|
Μορφή: | Journal article |
Έκδοση: |
American Medical Association
2018
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
ανά: Lotta, L, κ.ά.
Έκδοση: (2018) -
Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
ανά: Lotta, L, κ.ά.
Έκδοση: (2016) -
Peningkatan rasio Low Density Lipoprotein Cholesterol dengan High Density Lipoprotein Cholesterol sebagai faktor resiko stroke iskemik
ανά: , ARITYAWAN, Fred Septo, κ.ά.
Έκδοση: (2007) -
Genome-wide association study of adipocyte lipolysis in the GENetics of adipocyte lipolysis (GENiAL) cohort
ανά: Kulyté, A, κ.ά.
Έκδοση: (2020) -
In vitro and in vivo lipolysis of plasma triglycerides increases the resistance to oxidative modification of low-density lipoproteins.
ανά: Skoglund-Andersson, C, κ.ά.
Έκδοση: (2003)